Kidney Biopsy Global Market Report 2024

A kidney biopsy, also referred to as a renal biopsy, is a medical procedure where a small sample of kidney tissue is extracted for microscopic analysis. This procedure is commonly conducted to diagnose kidney conditions, evaluate the severity of existing kidney diseases, or monitor treatment effectiveness. It plays a crucial role in identifying diverse kidney disorders such as glomerulonephritis, interstitial nephritis, and nephrotic syndrome, offering insights into the underlying causes of kidney dysfunction.

The primary types of kidney biopsy include percutaneous biopsy and surgical biopsy. Percutaneous biopsy involves inserting a needle through the skin to obtain tissue samples from the kidney for examination. This method is utilized in various clinical settings including cases of kidney failure, kidney transplantation, hematuria, and proteinuria. It is employed by hospitals, clinics, urology centers, tertiary care centers, and other healthcare facilities.

The kidney biopsy market research report is one of a series of new reports that provides kidney biopsy market statistics, including the kidney biopsy industry global market size, regional shares, competitors with kidney biopsy market share, detailed kidney biopsy market segments, market trends, and opportunities, and any further data you may need to thrive in the kidney biopsy industry. These kidney biopsy market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kidney biopsy market size has grown strongly in recent years. It will grow from $2.03 billion in 2023 to $2.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period can be attributed to several factors, increased prevalence of chronic kidney diseases, heightened awareness and emphasis on early diagnosis, growth in the geriatric population, expansion of healthcare infrastructure, enhanced government initiatives aimed at kidney disease management, and rising awareness regarding kidney health.

The kidney biopsy market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period can be attributed to several key factors, the increasing prevalence of kidney diseases, rising healthcare expenditure globally, growing awareness about the importance of early diagnosis and treatment of kidney conditions, expanding geriatric population requiring specialized care, rising demand for minimally invasive medical procedures, and increasing research activities focused on improving kidney health outcomes. Major trends expected in this period include advancements in biopsy techniques with a focus on minimally invasive approaches, adoption of sophisticated imaging technologies for precise diagnosis, integration of artificial intelligence to enhance diagnostic accuracy and treatment planning, and ongoing technological innovations in biopsy devices aimed at improving safety and efficacy. These trends are poised to drive significant advancements in kidney biopsy procedures and contribute to improved patient care and outcomes in the field of nephrology.

The increasing incidence of renal cancer is poised to drive growth in the kidney biopsy market. Renal cancer involves the unchecked proliferation of abnormal kidney cells, influenced by factors such as lifestyle changes, environmental toxins, and improved diagnostic methods leading to higher detection rates. Kidney biopsies play a crucial role in diagnosing and managing renal cancer by confirming the presence of cancerous cells, determining cancer stage, guiding treatment strategies, monitoring treatment response, and providing prognostic insights. For example, Cancer Research UK projects an anticipated rise in new kidney cancer cases from approximately 16,300 in 2023 to about 21,900 by 2025, underscoring the escalating demand for kidney biopsy services.

Leading companies in the kidney biopsy market are innovating by integrating artificial intelligence (AI) to enhance diagnostic precision, streamline procedures, and optimize patient outcomes. AI technology improves kidney biopsy analysis by enhancing image interpretation, supporting diagnostic decisions, assisting in treatment planning, offering predictive analytics, and advancing research in kidney diseases. For instance, Aiosyn, a Netherlands-based software firm, introduced the NephroPath platform in March 2024. This platform utilizes computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including tissue type identification, measurement of interstitial fibrosis, and precise quantification and evaluation of glomeruli. Such AI-driven analysis ensures consistent, detailed, and reproducible assessment of renal pathology biomarkers, overcoming limitations associated with traditional scoring methods and reducing observer subjectivity.

In October 2022, Halma plc, a UK-based technology company, acquired IZI Medical Products for $176 million. This strategic acquisition enhances Halma plc's footprint in the kidney biopsy sector by integrating IZI Medical's advanced core biopsy devices. These devices are utilized across various anatomical sites, including kidneys, thyroid, intra-abdominal areas, and liver, aimed at improving the safety, accuracy, and efficacy of biopsy procedures. This acquisition underscores Halma plc's commitment to advancing biopsy technologies to benefit both patients and healthcare providers.

Major companies operating in the kidney biopsy market are Cardinal Health, Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Medtronic, Siemens Healthcare Private Limited, Becton, Dickinson and Company, Stryker Healthcare, Baxter International Inc., Boston Scientific Corporation, F. Hoffmann-La Roche Ltd., Zimmer Biomet, Agilent Technologies Inc., Olympus Corporation, Hitachi High-Tech Corporation, Beckman Coulter Inc., B. Braun, Sysmex Corporation, Cook Medical, Bio-Rad Laboratories Inc., Integra LifeSciences Corporation, Merit Medical Systems, Leica Biosystems Nussloch GmbH, Argon Medical Devices Inc., BioGenex.

North America was the largest region in the kidney biopsy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney biopsy market consists of revenues earned by entities by providing services such as diagnostic biopsy, therapeutic biopsy, post-biopsy care and monitoring, and pathological analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney biopsy market also includes sales of biopsy needles, biopsy guns, biopsy trays and kits, and biopsy specimen containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.